Study shows long-term efficacy for Ilumya in psoriasis
Sun Pharma’s Ilumya has proven to be efficient for up to three years of ongoing treatment.
Read More
Tag: tildrakizumab-asmn
US green lights new biologic for psoriasis
The US Food and Drug Administration has approved Sun Pharma’s Ilumya as a new treatment option for adults with moderate-to-severe plaque psoriasis.
Read More
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
